Company Overview: KITE

Upcoming Projects (KITE)

Don’t see a project related to the company you care about? Create your own!

Executed Projects (KITE)

Don’t see a project related to the company you care about? Create your own!

Upcoming & Overdue Catalysts (KITE)

Don’t see a catalyst related to the company you care about? Create your own!

Occurred Catalysts (KITE)

Kite Expects Investigational New Drug Application in 2018 for KTE-796 in Acute Myeloid Leukemia
Ticker: KITE
Occurred on: Feb 09, 2021
Kite Expects Phase 1 ZUMA-6 Data in 2017 Evaluating KTE-C19 in DLBCL and PD-L1 mAb
Ticker: KITE
Occurred on: Dec 03, 2018
Kite Expects Investigational New Drug Application in 2018 for KTE-439 in Cervical Cancer and Head and Neck Cancer
Ticker: KITE
Occurred on: Oct 02, 2018
Kite Expects First Patient Enrollment in 2017 for ZUMA-8 Trial Evaluating KTE-C19 in Chronic Lymphocytic Leukemia
Ticker: KITE
Occurred on: Aug 09, 2018
Kite Expects Data in 2018 From Phase 2 ZUMA-2 Study Evaluating KTE-C19 in Mantle Cell Lymphoma
Ticker: KITE
Occurred on: Jun 01, 2018
Kite Expects First Patient Enrollment in 2017 for ZUMA-7 Trial Evaluating KTE-C19 in BLBCL
Ticker: KITE
Occurred on: Jan 15, 2018
Gilead(GILD)'s Yescarta (Axicabtagene Ciloleucel) First CAR T Therapy Approved by the FDA for the Treatment of Adult Patients With Relapsed or Refractory Large B-Cell Lymphoma After Two or More Lines of Systemic Therapy
Tickers: GILD, KITE
Occurred on: Oct 18, 2017
Kite Pharma (KITE) on Track to Potentially Launch and Commercialize KTE-C19 in Late 2017
Ticker: KITE
Occurred on: Oct 18, 2017
Kite Expects Investigational New Drug Application in 2017 for KTE-585 in Multiple Myeloma
Ticker: KITE
Occurred on: Aug 08, 2017
Kite Expects First Patient Enrollment in Q1 2017 for ZUMA-5 Study Evaluating KTE-C19 in Indolent Non-Hodgkin Lymphoma
Ticker: KITE
Occurred on: May 08, 2017
Kite Expects Phase 1 Data in 2016 for huCD19 Study Evaluating KTE-C19 in B-Cell Malignancies
Ticker: KITE
Occurred on: Mar 14, 2017
Kite Primary Analysis of ZUMA-1 Trial Evaluating KTE-C19 in Aggressive Non-Hodgkin Lymphoma
Ticker: KITE
Occurred on: Feb 28, 2017
Kite Expects Phase 2 Data in 2017 for Expansion Study Evaluating KTE-C19 in Aggressive Non-Hodgkin Lymphoma
Ticker: KITE
Occurred on: Feb 08, 2017
Kite Expects Investigational New Drug Application in 2016 for KTE-718 in Non-Small Cell Lung Cancer and Bladder Cancer
Ticker: KITE
Occurred on: Jan 03, 2017
Kite Pharma (KITE) Research with National Cancer Institute Evaluating T-Cell Therapy in KRAS Mutant Metastatic Colorectal Cancer Published in New England Journal of Medicine
Ticker: KITE
Occurred on: Dec 12, 2016
KITE Posts Phase 2 Interim Analysis of ZUMA-1 Trial Evaluating KTE-C19 in Chemorefractory Aggressive Non-Hodgkin Lymphoma (NHL) to be Presented at the American Society of Hematology (ASH) 58th Annual Meeting on December 6
Ticker: KITE
Occurred on: Dec 06, 2016
Kite Expects Initial Phase 1 ZUMA-4 Data in 2016 Evaluating KTE-C19 in Pediatric Acute Lymphoblastic Leukemia
Ticker: KITE
Occurred on: Dec 04, 2016
Kite Expects Initial Phase 1 ZUMA-3 Data Evaluating KTE-C19 in Adult Acute Lymphoblastic Lymphoma in 2016
Ticker: KITE
Occurred on: Dec 04, 2016
Kite Pharma (KITE) expects to file for Biologics License Application (BLA) for KTE-C19 before 2017
Ticker: KITE
Occurred on: Dec 04, 2016
Juno Therapeutics (JUNO) Suspends Phase 2 ROCKET Study Assessing JCAR015 in Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia
Tickers: JUNO, KITE, CLLS
Occurred on: Nov 23, 2016
Kite Pharma Initiates Phase 1b/2 Combination Study for KTE-C19 and Atezolizumab in Patients with Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Ticker: KITE
Occurred on: Oct 06, 2016
Interim Results from Pivotal Phase 2 Portion of ZUMA-1 Clinical Trial of KTE-C19 Expected in September 2016
Ticker: KITE
Occurred on: Sep 26, 2016
Kite Pharma Licenses Enabling Technology for the Development of Off-the-Shelf Allogeneic T-Cell Therapies
Ticker: KITE
Occurred on: Jul 25, 2016
FDA has removed the clinical hold on the Phase II clinical trial of JCAR015 (known as the “ROCKET” trial) in adult patients with relapsed or refractory B cell acute lymphoblastic leukemia (r/r ALL)
Tickers: JUNO, CLLS, KITE, BLUE, ZIOP
Occurred on: Jul 12, 2016
Kite Pharma Completes Enrollment of All Patients with Diffuse Large B-Cell Lymphoma (DLBCL) in Pivotal Multi-Center Phase 2 Study of KTE-C19 (ZUMA-1)
Ticker: KITE
Occurred on: Jul 07, 2016
Kite Pharma Expands Development of T-Cell Receptor (TCR) Therapies Targeting HPV-Associated Cancers in Partnership with the National Cancer Institute (NCI)
Ticker: KITE
Occurred on: Jun 20, 2016
Complete Remission Rate of 90%: China-based CAR-T Cell Therapy Achieves Breakthrough Clinical Trial Results
Tickers: INNOVATIVE CELLULAR THERAPEUTICS, NVS, JUNO, KITE
Occurred on: May 06, 2016
Leukemia Research presented at American Association for the Advancement of Science (AAAS) leads to boost for CAR-T developers
Tickers: BLUE, KITE, CLLS, ZIOP, JUNO, BLCM, CYAD, ADAP
Occurred on: Feb 16, 2016
NIH study results of off-the-shelf CAR-Ts pose threat to designer CAR-T producers Kite Pharma (KITE) and Juno Therapeutics (JUNO)
Tickers: KITE, CLLS, JUNO
Occurred on: Jan 26, 2016
Kite Pharma (KITE) Prices Public Offering of 3.625M shares of common stock at $69 per share
Ticker: KITE
Occurred on: Dec 11, 2015
FDA designates Kite Pharma's (KITE) KTE-C19 a Breakthrough Therapy for the treatment of Refractory Diffuse Large B cell Lymphoma, Primary Mediastinal B Cell Lymphoma and Transformed Follicular Lymphoma
Ticker: KITE
Occurred on: Dec 07, 2015
Kite Pharma (KITE) to launch Phase 1 studies ZUMA-3 and ZUMA-4 Assessing KTE-C19 in Patients with Acute Lymphoblastic Leukemia
Ticker: KITE
Occurred on: Nov 12, 2015
Kite Pharma (KITE) Announces the Initiation of ZUMA-2, a second Phase 2 study for KTE-C19 Assessing Patients with Relapsed or Refractory Mantle Cell Lymphoma
Ticker: KITE
Occurred on: Nov 12, 2015
Kite Pharma (KITE) Opens Enrollment in Phase 2 Portion of ZUMA-1 Assessing KTE-C19 in Patients With Refractory Aggressive Non-Hodgkin's Lymphoma
Ticker: KITE
Occurred on: Nov 02, 2015
European Medicines Agency Adopts Positive Opinion Recommending Kite Pharma's (KITE) KTE-C19 for Orphan Treatment Designation for Advanced Hematological Cancers
Ticker: KITE
Occurred on: Oct 15, 2015

Strategic Initiatives (KITE)

Gilead Sciences (GILD) to Acquire Kite Pharma (KITE) for $11.9 Billion
Tickers: GILD, KITE
Announcement Date: Aug 28, 2017
Kite Forms Joint Venture with Shanghai Fosun Pharmaceutical Group (SFOSF) to Develop, Manufacture and Commercialize Axicabtagene Ciloleucel
Tickers: KITE, SFOSF
Announcement Date: Jan 10, 2017
Kite Agrees to Development and Commercialization Deal with Daiichi Sankyo (DSNKY) for Lead Product Candidate Axicabtagene Ciloleucel (KTE-C19) in Japan
Tickers: KITE, DSNKY
Announcement Date: Jan 09, 2017
Novartis disbands its pioneering cell and gene therapy unit
Tickers: NVS, JUNO, KITE
Announcement Date: Aug 31, 2016
BioLife Solutions Executes 10 Year Supply Agreement with Kite Pharma for CryoStor Use in CAR T Cell Therapies
Tickers: BLFS, KITE
Announcement Date: Jul 11, 2016

KITE Overview